- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099006
Novel Topical Therapies for the Treatment of Genital Pain (Topicals)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Vulvodynia is defined as burning pain, occurring in the absence of any visible finding or a clinically identifiable nervous disorder. Current treatments include vulvar care measure, topical medications, oral medications, biofeedback, physical therapy and surgery. The usual treatment is to have the patient take either tricyclic antidepressants or anti convulsants orally, however these methods seldom bring total relief. These drugs do have significant side effects limiting the patient's tolerance of the higher does sometimes needed. An effective topical medication would greatly benefit these women with fewer side effects and better tolerance. Topical amitriptyline and baclofen are often prescribed, but no studies have been done to support their use. Topical gabapentin has also been shown to have good effect, but no prospective clinical study as been done.
This study will test topical application of Cetaphil, Loperamide, Gabapentin, Ketoprofen, Ketamine and Amitriptyline over a 19 week period in the first phase of the study. The drugs are compounded by the University of Rochester research pharmacy and dispensed in 19 vials, one vial to be used each week. Patients and study personnel are blinded as to which drug is being used. Each study participant was given a week of placebo at the initiation of the study. Each study compound, which contains both the drug and the base (Cetaphil) will be used twice a day for two weeks in a row, followed by a one week washout of base alone. If a patient finds that one of the drugs is effective she may stop participation after the first 13 weeks and request that the most effective drug be prescribed for her. The unblinding officer would then work with the research pharmacy to identify the effective drug and provide the patient with a prescription for that drug. If the patient desires, she may enroll in the second phase of the study when she will test the last two drugs over a six week period with the washout as in the first segment of the study. The drugs would be administered in vials as in the first section of the study.
Every week on Sunday the patient will complete an electronic diary, recording her daily pain, any drug side effects, pain with the tampon test and overall health. Every three weeks she will complete the Female Sexual Function Index on the same electronic system. She would start her new drug on Monday each week. Additionally the coordinator of the study will call each patient on Wednesday to see if they are having any problems with the drug started on Monday.
All patients who could become pregnant are required to maintain effective contraception throughout the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women between ages of 18 and 65 who complain of localized provoked vulvar pain and meet the criteria for the diagnosis of localized provoked vulvodynia. Patients who have failed or have been unable to tolerate previous attempts at systematic therapy or surgery will be specifically recruited.
Exclusion Criteria:
- The presence of a dermatologic or neurologic condition which is determined by the investigator to be the primary cause of the patient's pain.
- Allergy to any of the medications or the base itself.
- Concurrent use of the following medications. . The patient may enroll in the study after a two week washout from these medications. Patients may need to receive approval from the prescribing physician before stopping these medications. Failure to obtain approval for medication cessation would be cause for exclusion.
Gabapentin (NeurontinTM) Amitriptyline (ElavilTM) Nortriptyline (PamelorTM) Desipramine (NorpraminTM) Tramadol (UltramTM, ConZipTM, RybixTM, RysoltTM, Ultram ERTM) Pregabalin (LyricaTM) Baclofen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medications
Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order.
The study is designed as a double blinded, crossover study.
|
Topical application of the drug at a 2% concentration in combination with 2% Baclofen
Other Names:
Used topically at 2% concentration in combination with 2% amitriptyline
Other Names:
To be applied topically at a 10% concentration
Other Names:
To be applied topically at a 10% concentration
Other Names:
To be applied topically at a 5% concentration
Other Names:
To be applied topically at a 6% concentration
Other Names:
|
Placebo Comparator: Placebo
The compounding base alone will be used as a placebo.
Each participant will be given each drug and the placebo sequentially in random order.
|
Compounding base to be used alone as a placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Daily Genital Pain.
Time Frame: 13 weeks
|
Each subject was asked to keep a symptom diary recording her daily genital pain, measured on a 10 point Likert scale.
A score of "0" was defined as no pain and a score of "10" was defined as worst imaginable pain.
These daily values were collected and a mean pain score for the period of treatment was calculated.
|
13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Tampon Test Pain
Time Frame: 13 weeks
|
Reduction in the pain, as measured on a 10 point Likert scale, associated with the insertion and removal of a tampon.
This is a validated surrogate for pain associated with intercourse.
Subjects were asked to insert and remove a tampon each week and report the degree of pain associated with this.
A score of "0" was defined as no pain, and a score of "10" was defined as worst imaginable pain.
|
13 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adrienne D Bonham, MD, University of Rochester
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Anti-Anxiety Agents
- GABA Agents
- Anticonvulsants
- Antidepressive Agents, Tricyclic
- Antimanic Agents
- Neuromuscular Agents
- Adrenergic Uptake Inhibitors
- Muscle Relaxants, Central
- GABA Agonists
- GABA-B Receptor Agonists
- Ketamine
- Gabapentin
- Amitriptyline
- Ketoprofen
- Baclofen
- Loperamide
- Antidiarrheals
Other Study ID Numbers
- 46905
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Genital Diseases
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...CompletedFemale Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusItaly
-
Arizona State UniversityCatholic Charities Phoenix; Phoenix International Refugee Committee; Refugee... and other collaboratorsCompletedFemale Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusUnited States
-
The University of Texas Medical Branch, GalvestonM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsActive, not recruitingMalignant Neoplasms of Female Genital OrgansUnited States
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Genewel Co., LtdUnknownGenital Diseases, FemaleKorea, Republic of
-
Nadezhda Women's Health HospitalMedical diagnostic laboratory ImunoVitaRecruitingFemale InfertilityBulgaria
-
M.D. Anderson Cancer CenterCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Liliana Berenice Ramírez DomínguezCompletedInfertility, Female | Infertility, MaleMexico
-
Uppsala UniversityMalmö UniversityCompletedFemale Circumcision | Female Genital Mutilation/CuttingSweden
-
Alexandria UniversityCompleted
Clinical Trials on Amitriptyline
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Peripheral Nervous System DiseaseUnited States
-
First Affiliated Hospital of Zhejiang UniversityHunan DongtingPharm.Co.LtdCompleted
-
AlgoTherapeutixCompleted
-
Gil YosipovitchTerminated
-
University of Missouri, Kansas CityRecruitingAutism Spectrum Disorder | Repetitive Compulsive BehaviorUnited States
-
UMC UtrechtUtrecht UniversityTerminatedChronic Neuropathic PainNetherlands
-
University Hospital TuebingenCompletedCystic Fibrosis | Infection | Pseudomonas AeruginosaGermany
-
CAMC Health SystemNational Institutes of Health (NIH); National Institute of General Medical... and other collaboratorsUnknownGallbladder DyskinesiaUnited States
-
Tufts Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Mayo ClinicRecruitingInterstitial Lung DiseaseUnited States